Profectus lands $9.5M defense contract for broader Ebola vaccine
By Scott Dance,The Baltimore Sun
Profectus BioSciences announced Friday its third round of government investment this month for an Ebola vaccine, receiving a $9.5 million contract from the U.S. Department of Defense.
The Baltimore-based company has received nearly $27 million this month from the defense department and Department of Health and Human Services, and $32 million in all since the ongoing Ebola outbreak began in West Africa late last year.
Unlike previous investments that focused on a vaccine designed specifically for the strain of Ebola present in the outbreak, Profectus' most recent contract focuses on a vaccine that would offer more broad protection against two types of Ebola as well as the Marburg virus, which causes hemorrhagic fever similar to Ebola.
Read more at http://www.baltimoresun.com/health/bs-bz-profectus-ebola-investments-20141031-story.html
Profectus BioSciences announced Friday its third round of government investment this month for an Ebola vaccine, receiving a $9.5 million contract from the U.S. Department of Defense.
The Baltimore-based company has received nearly $27 million this month from the defense department and Department of Health and Human Services, and $32 million in all since the ongoing Ebola outbreak began in West Africa late last year.
Unlike previous investments that focused on a vaccine designed specifically for the strain of Ebola present in the outbreak, Profectus' most recent contract focuses on a vaccine that would offer more broad protection against two types of Ebola as well as the Marburg virus, which causes hemorrhagic fever similar to Ebola.
Read more at http://www.baltimoresun.com/health/bs-bz-profectus-ebola-investments-20141031-story.html
